Pharmacyclics — Merger or Acquisition (March 2015)
20 slides from Pharmacyclics's merger presentation, Mar 5, 2015
Slide 1: AbbVie's Acquisition of Pharmacyclics
ABBVIE’S ACQUISITION OF PHARMACYCLICS March 5, 2015
Slide 2: Disclaimer and Forward-Looking Statement
2 Disclaimer and Forward-Looking Statement 2 This presentation and its contents are confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. This presentation is neither an offer to purchase nor a
Slide 3: Strategically Compelling Acquisition
Strategically Compelling Acquisition 3 Well-positioned for leadership in the large and rapidly growing oncology market Companies well-aligned with complimentary strengths and assets A strategically compelling and financially attractive combination to drive significant shareholder value Significantly
Slide 4: Strong Strategic Fit
Strong Strategic Fit Complementary strategic capabilities: Pharmacyclics Strong expertise in kinase biology and oncology discovery Organizational expertise/capabilities in oncology development Established strong commercial channel in hematological oncology AbbVie Strong pre-clinical discovery and de
Slide 5: Financially Compelling Opportunity
Financially Compelling Opportunity 5 Provides financially attractive profile, with accretion beginning in 2017, accelerating to more than $0.60 per share in 2019, and ramping significantly thereafter Exceeds our cost of capital hurdle rate by 2019, significantly exceeds it thereafter Purchase price
Slide 6: Financial Details
Financial Details AbbVie to acquire Pharmacyclics for $261.25 per share in cash and stock Represents 39% premium to the Pharmacyclics closing price on February 24, 2015 Implies transaction value of approximately $20.2BN net of cash acquired Pharmacyclics shareholders have option to elect 100% cash,
Slide 7: Strong Strategic Fit Drives Significant Value
7 Strong Strategic Fit Drives Significant Value Accelerates AbbVie’s leadership position in oncology Provides access to large and rapidly growing on-market asset with potential to achieve >$7BN peak-year AbbVie sales Accretive to EPS growth beyond 2016; ramping to >$0.60 per share by 2019 Complement
Slide 8: Hematologic Oncology Represents Significant Opportunity
Hematologic Oncology Represents Significant Opportunity 8 Global Hematologic Oncology Market Myelodysplastic Syndrome (MDS) $1.5B Multiple Myeloma (MM) $7.1B Acute Lymphocytic Leukemia (ALL) $1.0B Chronic Lymphocytic Leukemia (CLL) $1.7B Chronic Myeloid Leukemia (CML) $5.9B Lymphoma $6.1B Acute Myel
Slide 9: B-cell malignancies are a broad and complex group of cancers
B-cell malignancies are a broad and complex group of cancers Arise from various developmental stages of the B lymphocyte, the cell type responsible for humoral (antibody-mediated) immunity Occur in several forms Leukemia: Primarily affecting the bone marrow and blood Lymphoma: Arising in the lymph n
Slide 10: IMBRUVICA Overview – Mechanism of Action
IMBRUVICA Overview – Mechanism of Action BCR Signaling Syk CD79a/b Lyn Syk Lyn CD19 PI3Kd ERK PLCg2 PIP2 PIP3 BTK PKCb IKK NFkB DAG IP3 Ca++ Nucleus IMBRUVICA is a novel and differentiated BTK-inhibitor Bruton’s tyrosine kinase (BTK) is an essential element of the B-cell receptor (BCR) signaling pat
Slide 11: IMBRUVICA Overview – Current Indications
IMBRUVICA Overview – Current Indications IMBRUVICA (ibrutinib) - potential backbone therapy in B-Cell Malignancies First-in-class with demonstrated progression free survival and overall survival advantages over Rituxan Targeting a $10BN+ market with significant growth potential Four FDA/EMA approval
Slide 12: IMBRUVICA Overview – Potential Expansion of Indications
IMBRUVICA Overview – Potential Expansion of Indications Source: Pharmacyclics Corporate Presentation, January 14, 2014 Extensive ongoing clinical program 58 clinical studies ongoing with 13 in Phase III 5,100 patients have been enrolled in IMBRUVICA (ibrutinib) clinical trials 800 investigators in 3
Slide 13: Combined Hematologic Oncology Portfolio Overview
Combined Hematologic Oncology Portfolio Overview 13 IMBRUVICA duvelisib venetoclax Mechanism of Action BTK Inhibition PI3K Inhibition BCL-2 Inhibition Indications Approved for use in refractory CLL, WM, second-line Mantle Cell Lymphoma Being investigated in multiple myeloma, follicular lymphoma, and
Slide 14: Robust Pipeline Spans Attractive Specialty Categories
Robust Pipeline Spans Attractive Specialty Categories 14 2-DAA Japan : HCV (GT1b) Humira: Hidradenitis Suppurativa Daclizumab: Multiple Sclerosis Atrasentan: Diabetic Nephropathy Elagolix: Endometriosis Humira: Uveitis Veliparib: Ovarian Cancer ABT-199: AML ABT-199: iNHL Duvelisib: iNHL ABT-414: Gli
Slide 15: AbbVie Mid- to Late-Stage Program Highlights: Other Oncology
AbbVie Mid-to Late-Stage Program Highlights: Other Oncology 15 Compound Details Veliparib Solid Tumors PARP-inhibitor, enhances the effectiveness of common DNA damaging cancer therapies Four Phase III studies currently underway Planning to begin Phase III development for ovarian cancer in 2015 Elotu
Slide 16: AbbVie Mid- to Late-Stage Program Highlights: Immunology
AbbVie Mid-to Late-Stage Program Highlights: Immunology 16 Compound Details GLPG0634 Rheumatoid Arthritis Crohn’s Disease Selective JAK-1 inhibitor being evaluated as potential treatment for RA and Crohn’s disease Phase IIB RA studies on track to read out this year ABT-494 Rheumatoid Arthritis Inter
Slide 17: AbbVie Mid- to Late-Stage Program Highlights: Other Programs
AbbVie Mid-to Late-Stage Program Highlights: Other Programs 17 Compound Details Zinbryta (daclizumab) Multiple Sclerosis Humanized antibody specific for IL2 receptor in development for relapsing remitting MS Strong pivotal trial results showed patients treated with Zinbryta had a statistically signi
Slide 18: 2015: Significant Late-Stage Pipeline Activity
2015: Significant Late-Stage Pipeline Activity 18 Key Data Readouts Regulatory Submissions Regulatory Approvals Key Phase Transitions and Clinical Trial Starts ABT-199: Data from R/R CLL 17p del study Elotuzumab: Phase III data in R/R multiple myeloma GLPG0634: Phase IIB data in RA ABT-494: Phase II
Slide 19: Strong Return of Cash to Shareholders
Strong Return of Cash to Shareholders 19 Significant and growing cash flow Recently increased quarterly dividend by 4%; following ~17% increase in late 2014 Since AbbVie inception in 2013, dividend has been increased nearly 28% Share buyback program in place; to be executed over next several years S
Slide 20: [LOGO]
[LOGO] THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ABBV - AbbVie to Acquire Pharmacyclics Conference Call EVENT DATE/TIME: MARCH 05, 2015 / 02:00PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2015 Thomson Reuters. All rights reserved. Republication or redistribution of